scholarly journals BRAF-MEK inhibitor combo approved for adjuvant melanoma therapy

2018 ◽  
Vol 16 (6) ◽  
pp. e228-e230
Author(s):  
Jane de Lartigue
Keyword(s):  
Mek Inhibitor ◽  
Melanoma Therapy

Are Human Tyrosinase and Related Proteins Suitable Targets for Melanoma Therapy?

2016 ◽  
Vol 16 (27) ◽  
pp. 3033-3047 ◽  
Author(s):  
Elina Buitrago ◽  
Renaud Hardré ◽  
Romain Haudecoeur ◽  
Hélène Jamet ◽  
Catherine Belle ◽  
...  
Keyword(s):  
Related Proteins ◽  
Human Tyrosinase ◽  
Melanoma Therapy

scholarly journals Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy

Drug Delivery ◽  
2021 ◽  
Vol 28 (1) ◽  
pp. 594-606
Author(s):  
Mingming Song ◽  
Wentao Xia ◽  
Zixuan Tao ◽  
Bin Zhu ◽  
Wenxiang Zhang ◽  
...  
Keyword(s):  
Self Assembled ◽  
Polymeric Nanocarrier ◽  
Melanoma Therapy

Treatment of a BRAF V600E Positive Ameloblastoma in a Pediatric Patient with MEK Inhibitor Monotherapy

FACE ◽  
2021 ◽  
pp. 273250162110051
Author(s):  
Steven Daws ◽  
Kongkrit Chaiyasate ◽  
Arshi Lehal
Keyword(s):  
Mapk Pathway ◽  
Case Reports ◽  
Radical Resection ◽  
Mek Inhibitor ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Targeted Chemotherapy ◽  
Odontogenic Epithelium ◽  
Genetic Landscape ◽  
Frequent Presence

Ameloblastomas are uncommon tumors of the odontogenic epithelium standardly treated with radical resection. Recent studies of the genetic landscape of ameloblastoma have revealed the frequent presence of the BRAF V600E mutation, suggesting a possible role for targeted chemotherapy. We present the case of a primary mandibular ameloblastoma found in a 13-year-old female with confirmed BRAF V600E mutation. Prior to invasive surgical intervention she was treated for 8 weeks with the MEK inhibitor trametinib, but her tumor demonstrated little radiographic, clinical, or histologic response. Previous case reports have shown ameloblastoma in adult patients to be responsive to other agents targeting the MAPK pathway. Our observations in the presented case demonstrate the need for further research into the utility of targeted chemotherapy in ameloblastoma treatment.

scholarly journals EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity

Leukemia ◽  
2021 ◽  
Author(s):  
Johannes Lorenz Berg ◽  
Bianca Perfler ◽  
Stefan Hatzl ◽  
Barbara Uhl ◽  
Andreas Reinisch ◽  
...  
Keyword(s):  
Mek Inhibitor ◽  
Ras Signaling ◽  
Myeloid Neoplasms
Sign in / Sign up

Export Citation Format

Share Document